INTRODUCTION AND OBJECTIVES: It remains the standard approach for assessing the prognosis of mRCC patients treated with molecular-targeted agents to use the MSKCC and IMDC risk classifications, while the significant prognostic impact of the objective tumor response to these novel agents in mRCC patients has recently been documented in various studies. We also reported that the overall survival (OS) in patients with mRCC was closely correlated with the degree of tumor shrinkage at 12 weeks after the introduction of first-line targeted agents (Target Oncol 2016; 11: 175-82). Of these, however, there was no study focusing on data from mRCC patients treated with second-line targeted agents outside clinical trials. The objective of this study was to evaluate the impact of early tumor shrinkage (ETS) induced by a second-line targeted agent on OS in mRCC patients.
INTRODUCTION AND OBJECTIVES: It remains the standard approach for assessing the prognosis of mRCC patients treated with molecular-targeted agents to use the MSKCC and IMDC risk classifications, while the significant prognostic impact of the objective tumor response to these novel agents in mRCC patients has recently been documented in various studies. We also reported that the overall survival (OS) in patients with mRCC was closely correlated with the degree of tumor shrinkage at 12 weeks after the introduction of first-line targeted agents (Target Oncol 2016; 11: 175-82) . Of these, however, there was no study focusing on data from mRCC patients treated with second-line targeted agents outside clinical trials. The objective of this study was to evaluate the impact of early tumor shrinkage (ETS) induced by a second-line targeted agent on OS in mRCC patients.
METHODS: This study retrospectively included 271 consecutive Japanese patients with mRCC who received second-line targeted therapy for at least 3 months. ETS was defined as the degree of tumor shrinkage at the first post-baseline radiological evaluation conducted 4 to 8 weeks after initiating second-line targeted therapy. RESULTS: Of the 271 patients, 26 had ETS from -100 to -50%, 70 from -49 to -25%, 84 from -24 to 0%, and the remaining 91 failed to achieve a reduction in the tumor size. The median OS following the initiation of second-line targeted therapy stratified according to ETS was 45.8, 30.9, 22.1 and 14.2 months, respectively. Univariate analysis identified prior nephrectomy, the MSKCC risk classification, C-reactive protein (CRP) level, number of metastatic organs, sarcomatoid feature, introduced second-line agent and ETS induced by a second-line agent as parameters significantly associated with OS, of which, only the MSKCC classification, CRP level and ETS appeared to have independent impacts on OS on multivariate analysis.
CONCLUSIONS: Collectively, these findings suggest that ETS at the first post-baseline assessment under treatment with a second-line targeted agent could serve as a useful parameter with an independent impact on OS in mRCC patients receiving second-line targeted therapy; therefore, it is highly recommended to select second-line targeted agents that make it possible to induce prompt tumor remission to further improve the prognosis of patients with mRCC following the failure of first-line targeted therapy.
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MP16-06 EARLY RESPONSE AT FOUR WEEKS OF C-REACTIVE PROTEIN PREDICTS SURVIVAL IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH TYROSINE KINASE INHIBITORS
Yosuke Yasuda*, Kazutaka Saito, Naoko Kawamura, Sho Uehara, Takeshi Yuasa, Minato Yokoyama, Junichiro Ishioka, Yoh Matsuoka, Shinya Yamamoto, Shunji Takahashi, Tokyo, Japan; Tetsuo Okuno, Ibaraki, Japan; Junji Yonese, Kazunori Kihara, Yasuhisa Fujii, Tokyo, Japan INTRODUCTION AND OBJECTIVES: C-reactive protein (CRP) is a potential biomarker for renal cell carcinoma (RCC) (Saito K, Nat Rev Urol, 2011). The dynamic change of CRP levels, CRP kinetics, is associated with survival of patients with metastatic RCC (mRCC) in the cytokine era. We previously reported that early CRP response could predict overall survival (OS) for mRCC patients treated with tyrosine kinase inhibitors (TKI) in EAU congress 2016. In this study, we further explored whether the early CRP response could predict progressionfree survival (PFS) and response rates (RR) with more number of cases.
METHODS: A total of 103 patients (80 men and 23 women) were treated with TKI for mRCC from 2008 to 2013 at our institutions. Overall, 43 and 60 patients were treated with sunitinib and sorafenib, respectively. Fifty patients (49%) had received prior immunotherapy, and 69 patients (67%) had undergone nephrectomy previously. Baseline CRP elevation was defined as a level of 10 mg/L or more. Patients were divided into three groups according to their early CRP kinetics: patients whose baseline CRP levels were <10 mg/L (non-elevated group), patients whose baseline CRP levels were 10 mg/L or more and had decreased by more than 20% 4 weeks after the initiation of TKI (early CRP responder), and the remaining patients (non-early CRP responder). The endpoints were OS, PFS and RR.
RESULTS: The median follow up period was 21 months (range 1 to 79 months). Baseline CRP levels were elevated in 41 patients (40%). Among these 41 patients, 19 (18%) were early CRP responder. The 1-year OS and PFS rates for the entire cohort were 69% and 40%, respectively. The 1-year OS rates of non-elevated group, early CRP responder, and non-early CRP responder were 79%, 62%, and 36% (p < 0.001). The 1-year PFS rates of these three groups were 50%, 23%, and 10% (p < 0.001). In multivariate analysis, the early CRP kinetics assessment was a significant independent factor for OS and PFS. Though there were no significant differences in the objective response rates between these three groups (p ¼ 0.56), significantly more patients had progressive disease in the non-early CRP responder (p ¼ 0.02).
CONCLUSIONS: Early CRP response at 4 weeks is predictive of survival for patients with mRCC treated with TKI.
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